AZD9833 China PK Study
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- ER+, HER2-, Metastatic Breast Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 130 years
- Gender
- Only males
Description
This study is designed to investigate and characterize the safety, tolerability and PK of AZD9833 monotherapy (Part A, Part B-cohort 1) and in combination with palbociclib (Part B cohort 2) or everolimus (Part B cohort 3) and to explore the preliminary anti-tumour activity in Chinese patients.
This study is designed to investigate and characterize the safety, tolerability and PK of AZD9833 monotherapy (Part A, Part B-cohort 1) and in combination with palbociclib (Part B cohort 2) or everolimus (Part B cohort 3) and to explore the preliminary anti-tumour activity in Chinese patients.
Tracking Information
- NCT #
- NCT04818632
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Jiong Wu Department of Breast Surgery, Fudan University Shanghai Cancer Center Principal Investigator: Jian Zhang Department of Medical Oncology, Fudan University Shanghai Cancer Center
Get Well Soon